Opinion|Videos|June 6, 2025
Addressing Critical Gaps in the Management of NSCLC and the Importance of the Next Wave of Treatment Advances
Author(s)Lauren Ledbetter, PharmD, BCOP
A panelist discusses how emerging research in non–small cell lung cancer (NSCLC) is focused on determining the most effective neoadjuvant/adjuvant approaches combining chemotherapy with immunotherapy, addressing tumor heterogeneity through potential combinations of targeted therapies, and investigating mechanisms of immunotherapy nonresponse to improve patient outcomes.
Advertisement
Episodes in this series
Current Research Challenges
- Early-stage NSCLC:
- Multiple FDA approvals for neoadjuvant/adjuvant chemoimmunotherapy; awaiting mature data to establish optimal approach
- Tumor heterogeneity: Multiple targetable mutations often present; no current data on combining targeted therapies
- Immunotherapy nonresponders: Research needed to understand mechanisms of nonresponse and identify additional targets
- Focus on minimizing toxicity exposure when benefit cannot be guaranteed
Advertisement
Related to this article
An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-quarters of treated patients.
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
IRAKLIA shows isatuximab OBI boosts comfort and satisfaction vs IV in multiple myeloma, enabling fast at-home dosing with strong completion.
Gut microbiome disruption from anti-anaerobic antibiotics weakens CAR T cell therapy, raising relapse and CRS/ICANS risk; stewardship and microbiome repair may improve cancer outcomes.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
4
Influenza Vaccines Continue to Reduce Severe Disease and Death Across High-Risk Groups, Evidence Review Finds
5